Determinants of health-related quality of life decline in interstitial lung disease

Maqhuzu, Phillen Nozibuyiso; Szentes, Boglárka; Kreuter, Michael; Bahmer, Thomas; Kahn, Nicolas; Claussen, Martin; Holle, Rolf; Schwarzkopf, Larissa

doi:10.1186/s12955-020-01570-2

Cited by 10 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with our findings, illness perception positively associated with fear of progression (Shim et al, 2018). As the disease progresses, the exacerbation of patients' symptoms, the increase in economic cost and the accumulation of side effects will cause psychological, physiological and social impacts on patients (Maqhuzu et al, 2020;Yuan et al, 2019). At this time, it is necessary to accept the diagnosis and treatment of ILD emotionally and psychologically.…”

Section: Discussionsupporting

confidence: 85%

Relationship between illness perception, fear of progression and quality of life in interstitial lung disease patients: A cross‐sectional study

Liu

Qin

et al. 2021

Journal of Clinical Nursing

View full text Add to dashboard Cite

Aims and objectives:This study aimed to investigate whether fear of progression mediates the association between illness perception and quality of life among interstitial lung disease patients.Background: So far, the physiological treatment of interstitial lung disease is limited.In addition to immunosuppressants such as glucocorticoids, two anti-fibrosis drugs (pirfenidone and nintedanib) have shown moderately beneficial effects on slowing the progression of interstitial lung disease fibrosis. However, none of these drugs has shown reliable or strong beneficial effects on improving quality of life. Psychological care and mental health support strategies focusing on improving patients' quality of life are particularly important. Design: A cross-sectional study.Methods: A convenience sample of patients suffering from interstitial lung disease were enrolled from August to December 2019. Data including sociodemographic and clinical characteristics, illness perception, fear of progression and quality of life were collected. The descriptive analysis and Pearson correlations were analysed by SPSS 26.0 (IBM Corp.). PROCESS v3.4 (by Andrew F. Hayes) macro was applied to analyse the mediating effects. We used the STROBE checklist to report the results.Results: Both illness perception and fear of progression were correlated with quality of life. Fear of progression mediated the association between illness perception and quality of life. The indirect effect was 0.121, and the proportion of intermediary effect in the main effect was 26.36%. Conclusion:Interstitial lung disease patients experience relatively poor quality of life and fear of progression exerts a mediating role between illness perception and quality of life. Relevance to clinical practice:This study alerts medical staff to pay attention to negative illness perception and excessive fear, which is helpful to formulate effective interventions to manage interstitial lung disease patients' quality of life.

show abstract

Section: Discussionsupporting

confidence: 85%

Relationship between illness perception, fear of progression and quality of life in interstitial lung disease patients: A cross‐sectional study

Liu

Qin

et al. 2021

Journal of Clinical Nursing

View full text Add to dashboard Cite

show abstract

“…Interestingly, other studies that have investigated HRQOL with disease specific tools in Chronic Obstructive Pulmonary Disease and ILD also did not identify a significant association between HRQOL and pulmonary function parameters. 19,20 Taken as a whole, other objective markers of disease severity such as pulmonary hemodynamics, laboratory values and pulmonary function measurements did not directly translate to impairments in HRQOL in PH-CLD. While the lack of association between HRQOL and pulmonary hemodynamics and lung function may be related to the length of time between diagnostic information and PRO assessment, such findings suggest that variables traditionally prioritized for disease assessment in clinical practice are not strongly associated with PROs.…”

Section: Discussionmentioning

confidence: 96%

Using PAH‐SYMPACT to assess quality of life in patients with pulmonary hypertension associated with chronic lung disease

Bailey,

Durst,

Cajigas

et al. 2024

Pulm. circ.

View full text Add to dashboard Cite

Chronic lung disease (CLD) is the second leading cause of pulmonary hypertension (PH) and is associated with significant morbidity and mortality. Although PH associated with CLD (PH‐CLD) leads to impaired health‐related quality of life (HRQOL), there are no validated tools to assess HRQOL in PH‐CLD. The Pulmonary Arterial Hypertension–Symptoms and Impact Questionnaire (PAH‐SYMPACT) is an HRQOL instrument aimed at assessing the symptoms and impact of PH on overall function and well‐being. We performed a single‐center prospective cohort study using PAH‐SYMPACT scores to compare symptoms, exercise capacity and HRQOL in patients with PAH and PH‐CLD. One hundred and twenty‐five patients (99 patients with idiopathic/heritable PAH and 26 with PH‐CLD) completed the PAH‐SYMPACT questionnaire which consists of 22 questions that assess HRQOL across four domains: cardiopulmonary (CP) symptoms, cardiovascular (CV) symptoms, physical impact (PI), and cognitive/emotional (CE) impact. Higher scores indicate worse HRQOL. We compared patients with PAH and PH‐CLD using a Wilcoxon rank sum or chi‐squared test as appropriate. Multivariate linear regression analysis was used to assess the relationship between PH classification and SYMPACT scores. Compared to PAH, patients with PH‐CLD were older, more likely to use oxygen and had worse functional class and exercise capacity. While there was no significant difference between the two groups in CP, CV, or CE domain scores, patients with PH‐CLD had significantly worse PI scores by univariate (1.79 vs. 1.13, p < 0.001) and multivariate analysis (1.61 vs. 1.17, p = 0.02) and overall worse SYMPACT scores (1.19 vs. 0.91, p = 0.03). In conclusion, patients with PH‐CLD have worse HRQOL as assessed by the PAH‐SYMPACT questionnaire versus patients with PAH. Although PAH‐SYMPACT has not been validated in PH‐CLD, the results of this study can guide clinicians in understanding the symptoms and impact of PH‐CLD relative to PAH.

show abstract

“…Our study showed that the DLCO %pred, but not FVC %pred, is a significant predictor of poor K-BILD total, ‘psychological’ and ‘breathlessness and activities’ domains in ILD patients. Indeed, a lower baseline DLCO %pred is associated not only with poorer HRQL ( 25 , 34 ) but also with future HRQL deterioration ( 16 , 41 ). Even though the degree of reduction in DLCO usually mirrors the corresponding drop in FVC, a severe reduction in DLCO may represent the presence of pulmonary hypertension on top of lung parenchymal destruction from ILD, and pulmonary hypertension has been shown to decrease the quality of life in IPF patients ( 42 ).…”

Section: Discussionmentioning

confidence: 99%

Health-related quality of life in a multiracial Asian interstitial lung disease cohort

Phua¹,

Tan²,

Phua³

et al. 2022

J Thorac Dis

View full text Add to dashboard Cite

Background: Understanding health-related quality of life (HRQL) in patients with interstitial lung disease (ILD) provides insight into disease burden and treatment effects on patients' well-being. We examined HRQL in a multiracial Asian ILD cohort using the King's brief ILD (K-BILD) and EuroQol 5-dimension-3-level (EQ5D-3L) questionnaires and their associations with several clinical variables.Methods: This was a single-centre cross-sectional study of ILD patients in a university-affiliated tertiary public hospital in Singapore. All patients completed two self-administered HRQL questionnaires upon study entry, and their clinical information was retrieved from electronic medical records.Results: Ninety-nine patients (56% male, 75% Chinese) were included. The median (interquartile range) age was 63 (54-72) years. The most common ILD diagnosis was connective tissue disease-related ILD (n=51, 52%), followed by idiopathic pulmonary fibrosis (n=27, 27%). The mean (standard deviation) scores for the EQ5D-3L utility value, EQ5D Visual Analogue Scale (VAS) and K-BILD total were 0.806 (0.284), 75.1 (12.8) and 63.9 (14.3), respectively. A moderate correlation was found between the EQ5D-3L and K-BILD total and domain scores. The HRQL scores also correlate moderately with the modified Medical Research Council dyspnoea scale (mMRC) scores. There was a weak-to-moderate correlation between HRQL and FVC, DLCO and Charlson comorbidity index. Multiple linear regression showed a significant association of K-BILD total (beta coefficient 0.244, 95% CI: 0.075-0.414; P=0.005), K-BILD 'breathlessness and activities' (beta coefficient 0.448, 95% CI: 0.192-0.703; P=0.001), and the 'psychological' domain (beta coefficient 0.256, 95% CI: 0.024-0.488; P=0.031) with DLCO %pred after adjustment for age, sex, BMI, race, smoking history, comorbidities, FVC %pred and ILD diagnosis. Non-Chinese race was a predictor of better K-BILD

show abstract

Determinants of health-related quality of life decline in interstitial lung disease

Cited by 10 publications

References 40 publications

Relationship between illness perception, fear of progression and quality of life in interstitial lung disease patients: A cross‐sectional study

Relationship between illness perception, fear of progression and quality of life in interstitial lung disease patients: A cross‐sectional study

Using PAH‐SYMPACT to assess quality of life in patients with pulmonary hypertension associated with chronic lung disease

Health-related quality of life in a multiracial Asian interstitial lung disease cohort

Contact Info

Product

Resources

About